78 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
14 May 24
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results
5:00pm
Operating lease right-of-use assets
Long-term marketable securities
Long-term restricted cash
Other long-term assets
Total assets
Liabilities
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Long-term restricted cash
Other long-term assets
Total assets … of long-term debt
Total current liabilities
Operating lease liability, net of current portion
Long-term debt, net
Warrant liability
Total liabilities
8-K
EX-99.1
953l4ul
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
hj8hoy
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
EX-99.1
bugjvn8n rqf3jnpu5
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
j2mgu5q0huvrh6of4b5s
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.2
6pedis
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
4607gug
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
EX-99.2
7143 w4aq
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
EX-99.1
zbp1unmv ega
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am